X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1234) 1234
Conference Proceeding (338) 338
Publication (94) 94
Book Review (70) 70
Patent (20) 20
Book Chapter (19) 19
Magazine Article (4) 4
Book / eBook (2) 2
Reference (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (525) 525
humans (433) 433
hematology (273) 273
oncology (272) 272
female (212) 212
male (210) 210
animals (192) 192
middle aged (140) 140
adult (129) 129
aged (124) 124
mice (118) 118
expression (96) 96
cancer (90) 90
pathology (83) 83
neuroblastoma (81) 81
analysis (80) 80
prognosis (79) 79
cell line, tumor (72) 72
aged, 80 and over (71) 71
lymphomas (68) 68
cell biology (63) 63
immunohistochemistry (61) 61
medicine, research & experimental (61) 61
abridged index medicus (60) 60
biochemistry & molecular biology (54) 54
growth (54) 54
lymphoma (54) 54
neuroblastoma - pathology (53) 53
b-cell lymphoma (52) 52
apoptosis (51) 51
chemotherapy (49) 49
adolescent (48) 48
hemic and lymphatic diseases (47) 47
transplantation (47) 47
treatment outcome (47) 47
antineoplastic combined chemotherapy protocols - therapeutic use (46) 46
genetic aspects (45) 45
immunology (44) 44
mutation (44) 44
survival (43) 43
cells (42) 42
fisheries (42) 42
lymphoma, large b-cell, diffuse - drug therapy (42) 42
neurosciences (42) 42
research (42) 42
tumor cells, cultured (42) 42
non-hodgkins-lymphoma (41) 41
lymphoma, large b-cell, diffuse - genetics (40) 40
pharmacology & pharmacy (40) 40
sensors (40) 40
therapy (40) 40
tumors (40) 40
liposomes (39) 39
gene expression regulation, neoplastic (38) 38
health aspects (38) 38
multidisciplinary sciences (38) 38
biotechnology & applied microbiology (36) 36
rituximab (36) 36
gene expression profiling (35) 35
in-vivo (35) 35
gene expression (34) 34
neuroblastoma - drug therapy (34) 34
neuroblastoma - metabolism (34) 34
selection (34) 34
activation (33) 33
aquaculture (33) 33
genetics (32) 32
hematology, oncology and palliative medicine (32) 32
materials science, multidisciplinary (32) 32
proteins (32) 32
surgery (32) 32
differentiation (31) 31
genetics & heredity (31) 31
marine & freshwater biology (31) 31
rats (30) 30
care and treatment (29) 29
gene (29) 29
immune system diseases (29) 29
mice, nude (29) 29
antineoplastic agents - therapeutic use (28) 28
article (28) 28
risk factors (28) 28
angiogenesis (27) 27
lymphoma, large b-cell, diffuse - pathology (27) 27
retinoic acid (27) 27
chemistry, analytical (26) 26
disease models, animal (26) 26
gas sensors (26) 26
lymphocytes (26) 26
neoplasm staging (26) 26
nile tilapia (26) 26
diffuse large b-cell lymphoma (25) 25
disease (25) 25
genetic research (25) 25
lymphoma, b-cell, marginal zone - pathology (25) 25
signal transduction (25) 25
apoptosis - drug effects (24) 24
chemistry, multidisciplinary (24) 24
doxorubicin (24) 24
survival analysis (24) 24
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9700, pp. 1512 - 1520
Summary Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy... 
Internal Medicine | DEFERRED RADIOTHERAPY | MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | INTERNATIONAL WORKSHOP | RESPONSE CRITERIA | EUROPEAN ORGANIZATION | CONSOLIDATING RADIOTHERAPY | NON-HODGKINS-LYMPHOMA | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Lymphoma, Non-Hodgkin - radiotherapy | Cranial Irradiation - methods | Central Nervous System Neoplasms - radiotherapy | Adult | Lymphoma, Non-Hodgkin - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Treatment Outcome | Combined Modality Therapy | Remission Induction | Methotrexate - adverse effects | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Aged | Lymphoma, Non-Hodgkin - mortality | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Cytarabine | Patient outcomes | Central nervous system diseases | Dosage and administration | Lymphomas | Drug therapy, Combination | Methotrexate | Drug therapy | Data analysis | Disease | Monoclonal antibodies | Data collection | Radiation therapy | Patients | Tropical diseases | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 5, pp. 489 - 500
Journal Article
Leukemia, ISSN 0887-6924, 2012, Volume 26, Issue 9, pp. 2103 - 2113
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 3, Issue 5, pp. e217 - e227
Summary Background Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | RESPONSE CRITERIA | GUIDELINES | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | CENTRAL-NERVOUS-SYSTEM | WHOLE-BRAIN RADIOTHERAPY | HIGH-DOSE CHEMOTHERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Lymphoma, B-Cell - therapy | Middle Aged | Male | Comparative Effectiveness Research | Hyperglycemia - chemically induced | Radiotherapy, Adjuvant - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Lymphoma, B-Cell - diagnostic imaging | Transplantation Conditioning - methods | Rituximab - adverse effects | Induction Chemotherapy - methods | Anemia - chemically induced | Central Nervous System Neoplasms - therapy | Thrombocytopenia - chemically induced | Mucositis - chemically induced | Magnetic Resonance Imaging | Methotrexate - adverse effects | Dexamethasone - therapeutic use | Radiotherapy, Adjuvant - methods | Transplantation, Autologous - adverse effects | Heart Injuries - chemically induced | Italy | Hematopoietic Stem Cell Transplantation - methods | Central Nervous System Neoplasms - mortality | Germany | Thiotepa - adverse effects | Thiotepa - therapeutic use | Thrombosis - chemically induced | Intraocular Lymphoma - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Methotrexate - therapeutic use | Infection - chemically induced | Rituximab - therapeutic use | Stroke - chemically induced | Optic Nerve Neoplasms - diagnostic imaging | Poisoning - epidemiology | Female | Remission Induction - methods | Transplantation Conditioning - adverse effects | Acute Kidney Injury - chemically induced | Neutropenia - chemically induced | Optic Nerve Neoplasms - therapy | Death, Sudden - epidemiology | Lymphoma, B-Cell - mortality | Intraocular Lymphoma - diagnostic imaging | Kaplan-Meier Estimate | Chemical and Drug Induced Liver Injury - epidemiology | Treatment Outcome | United Kingdom | Combined Modality Therapy - adverse effects | Switzerland | Induction Chemotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Central Nervous System Neoplasms - diagnostic imaging | Denmark | Combined Modality Therapy - methods | Neurotoxicity Syndromes - epidemiology | Gastrointestinal Diseases - chemically induced | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 2017, Volume 31, Issue 3, pp. 625 - 636
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 20, pp. 4021 - 4031
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal center B-cell (GCB)-like and unfavorable activated B-cell (ABC)-like... 
MOLECULAR SUBTYPES | PLUS CYCLOPHOSPHAMIDE | PROGNOSTIC IMPACT | R-CHOP | POOR-PROGNOSIS | T(14/18) | DISTINCT | PREDICTS SURVIVAL | HEMATOLOGY | NF-KAPPA-B | BCL-2 EXPRESSION | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | B-Lymphocyte Subsets - classification | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Transcriptome | Male | Proto-Oncogene Proteins c-bcl-2 - metabolism | Lymphocyte Activation - genetics | Aged, 80 and over | Vincristine - administration & dosage | Adult | B-Lymphocyte Subsets - immunology | Female | Retrospective Studies | Gene Expression Regulation, Neoplastic - physiology | Doxorubicin - administration & dosage | B-Lymphocyte Subsets - physiology | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Risk Factors | Rituximab | International Cooperation | Proto-Oncogene Proteins c-myc - metabolism | Lymphoma, Large B-Cell, Diffuse - mortality | Lymphoma, Large B-Cell, Diffuse - diagnosis | B-Lymphocyte Subsets - metabolism | Survival Analysis | Aged | Proto-Oncogene Proteins c-myc - genetics | Lymphoma, Large B-Cell, Diffuse - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Cohort Studies | Index Medicus | Abridged Index Medicus | Plenary Paper | CME
Journal Article
Journal Article
Molecular Psychiatry, ISSN 1359-4184, 05/2017, Volume 22, Issue 5, pp. 689 - 702
SHANK3 (also called PROSAP2) genetic haploinsufficiency is thought to be the major cause of neuropsychiatric symptoms in Phelan-McDermid syndrome (PMS). PMS is... 
POSITIVE ALLOSTERIC MODULATOR | METABOTROPIC GLUTAMATE-RECEPTOR | PSYCHIATRY | BIOCHEMISTRY & MOLECULAR BIOLOGY | SYNAPTIC-TRANSMISSION | SHANK3-DEFICIENT MICE | NEUROSCIENCES | POSTSYNAPTIC DENSITY PROTEINS | AUTISTIC-LIKE BEHAVIORS | HOMER-PROTEINS | MOUSE MODEL | FRAGILE-X-SYNDROME | OBJECT RECOGNITION | Chromosomes, Human, Pair 22 - metabolism | Exons | Nerve Tissue Proteins - deficiency | Male | Hippocampus - drug effects | Corpus Striatum - metabolism | Synaptic Transmission | Chromosomes, Human, Pair 22 - genetics | Behavior, Animal - drug effects | Mice, Inbred DBA | Benzamides - pharmacology | Neurons - metabolism | Post-Synaptic Density - metabolism | Neurons - drug effects | Pyrazoles - pharmacology | Chromosome Deletion | Homer Scaffolding Proteins - metabolism | Autism Spectrum Disorder - genetics | Signal Transduction | Chromosome Disorders - metabolism | Mice, Inbred C57BL | Receptor, Metabotropic Glutamate 5 - metabolism | Nerve Tissue Proteins - genetics | Mice, Knockout | Nerve Tissue Proteins - metabolism | Hippocampus - metabolism | Animals | Autism Spectrum Disorder - metabolism | Corpus Striatum - drug effects | Mice | Autism Spectrum Disorder - drug therapy | Chromosome Disorders - genetics | Psychological aspects | Genetic aspects | Research | Gene mutations | Mental illness | Risk factors | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 14, pp. 2715 - 2724
Journal Article
Journal Article